About Us
Equillium is a clinical-stage biotechnology company leveraging a deep
understanding of immunobiology to develop novel therapeutics to treat
severe autoimmune and inflammatory disorders with high unmet medical need.
The company’s pipeline consists of the following novel
first-in-class
immunomodulatory assets targeting
immuno-inflammatory pathways.
EQ101: a tri-specific cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15;
currently under evaluation in a Phase 2 proof-of-concept study of patients with alopecia areata.
EQ102: a bi-specific cytokine inhibitor that selectively targets IL-15 and IL-21; currently under evaluation in
a Phase 1 study to include healthy volunteers and celiac disease patients. Itolizumab: a monoclonal antibody
that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells;
currently under evaluation in a Phase 3 study for patients with acute
graft-versus-host disease (aGVHD) and a
Phase 1b study for patients with lupus/lupus nephritis.